Healthcare
Live Price
Offline$0.0018
-28.00% today
Window Change
-95.20%
Window
Jun 26, 2025 → Dec 29, 2025
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 116 bars · Jun 26, 2025 → Dec 29, 2025
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Clene Inc. (CLNNW) is a Healthcare stock with a market cap of $2.16M. The stock last traded around $0.00 and down 95.2% across the available one-year price window (Jun 26, 2025 → Dec 29, 2025). Baseline metrics include revenue growth of -41.5%, EPS growth of +53.3%, a dividend yield of 0.0%. What stands out right now is revenue -41.5%, EPS +53.3%, free cash flow +12.9% with operating margin -11541.5% and ROIC -188.6%. Valuation already assumes a fairly strong business story at price/sales 329.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CLNNW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CLNNW
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CLNNW Max Drawdown
-95.91%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CLNNW and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$723.0K
+52.9% YoY
FY Net Income
-$9.7M
+67.4% YoY
Free Cash Flow
-$36.0M
+18.6% YoY
Revenue Growth
-41.5%
EPS Growth
+53.3%
Gross Margin
78.5%
Net Margin
-13086.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 200K | 342K | 654K | 473K | 723K |
| Gross Profit | 157K | 272K | 533K | 447K | 434K |
| Operating Income | -23M | -33M | -41M | -48M | -50M |
| EBITDA | -22M | -34M | -43M | -26M | -8M |
| Net Income | -26M | -39M | -50M | -30M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 12M | 29M | 18M | 50M |
| Total Assets | 18M | 27M | 52M | 44M | 63M |
| Total Liabilities | 36M | 36M | 39M | 41M | 50M |
| Shareholder Equity | -18M | -9M | 13M | 3M | 13M |
| Total Debt | 22M | 21M | 32M | 32M | 24M |
| Net Debt | 16M | 9M | 3M | 13M | -26M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
35M
+11.2% YoY
Capital Expenditures
1M
+74.3% YoY
Free Cash Flow
36M
+18.6% YoY
Key ratios
Gross Margin
78.5%
Operating Margin
-11541.5%
Net Margin
-13086.5%
ROE
240.8%
Debt / Equity
-1.23x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.